Mikkel Zollner Ankarfeldt
Overview
Explore the profile of Mikkel Zollner Ankarfeldt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raket H, Ankarfeldt M, Wang J, Pressler T, Jensen-Fangel S, Qvist T, et al.
Pulm Ther
. 2025 Feb;
PMID: 39948204
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to substantially improve clinical outcomes among people living with cystic fibrosis (pwCF). The impact of ETI on health care resource utilization in the context...
2.
Christiansen F, Petersen J, Thorius I, Ladelund A, Jimenez-Solem E, Osler M, et al.
JAMA Netw Open
. 2024 May;
7(5):e249291.
PMID: 38691357
Importance: Becoming a first-time parent is a major life-changing event and can be challenging regardless of the pregnancy outcome. However, little is known how different adverse pregnancy outcomes affect the...
3.
Kliim-Hansen V, Johansson K, Gasbjerg L, Jimenez-Solem E, Petersen T, Nyeland M, et al.
Diabetes Obes Metab
. 2023 Oct;
26(1):160-168.
PMID: 37799010
Aim: To explore the impact of type 2 diabetes (T2D), glycaemic control and use of glucose-lowering medication on clinical outcomes in hospitalized patients with COVID-19. Materials And Methods: For all...
4.
Frost M, Jensen K, Gotfredsen D, Sorensen A, Ankarfeldt M, Louie K, et al.
Lung Cancer
. 2023 Mar;
178:172-182.
PMID: 36868178
Objectives: We aimed to characterize the advanced NSCLC population in terms of KRAS G12C prevalence, patient characteristics, and survival outcomes after the introduction of immunotherapies. Materials And Methods: We identified...
5.
Ankarfeldt M, von Osmanski B, Blond K
Pharmacoepidemiol Drug Saf
. 2023 Feb;
32(4):506-507.
PMID: 36737851
No abstract available.
6.
Ankarfeldt M, Petersen J, Traerup Andersen J, Fernandes M, Li H, Motsko S, et al.
Drugs Real World Outcomes
. 2022 Nov;
10(1):69-81.
PMID: 36355315
Background: Depression or depressive symptoms are common among pregnant women. The use of antidepressants during pregnancy has grown steadily. The risk of offspring being born small for gestational age or...
7.
Jensen K, Gronemann F, Ankarfeldt M, Jimenez-Solem E, Alulis S, Riise J, et al.
PLoS One
. 2022 Sep;
17(9):e0275299.
PMID: 36166443
Objectives: To investigate healthcare resource utilization (HRU) and associated costs by depression severity and year of diagnosis among patients with treatment-resistant depression (TRD) in Denmark. Methods: Including all adult patients...
8.
Thor Petersen C, Jensen K, Rosenzweig M, von Osmanski B, Ankarfeldt M, Petersen J
Clin Epidemiol
. 2022 May;
14:521-542.
PMID: 35502197
Purpose: There is an increasing need for national and international pharmacoepidemiological studies based on high-quality real-world data of which the Danish registries are a valuable source. In lack of a...
9.
Ankarfeldt M, Petersen J, Traerup Andersen J, Li H, Motsko S, Fast T, et al.
PLoS Med
. 2021 Nov;
18(11):e1003851.
PMID: 34807906
Background: The prevalence of depression and the exposure to antidepressants are high among women of reproductive age and during pregnancy. Duloxetine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) approved in...
10.
Ankarfeldt M, Petersen J, Traerup Andersen J, Fernandes M, Li H, Motsko S, et al.
Drugs Real World Outcomes
. 2021 May;
8(3):289-299.
PMID: 34008161
Background: Depression and antidepressant treatment are widespread among women of childbearing age. Objective: This study evaluates the association between duloxetine exposure during pregnancy and spontaneous and elective abortions. Patients And...